ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.33 Average PT from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $77.33.

ANIP has been the subject of several recent research reports. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 33,981 shares of company stock worth $1,970,066 over the last ninety days. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Innealta Capital LLC bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $65,000. Ridgewood Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $85,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. XTX Topco Ltd bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $207,000. Finally, HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $222,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ ANIP opened at $56.97 on Monday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a 50 day moving average price of $58.05 and a 200 day moving average price of $60.44. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The stock has a market cap of $1.20 billion, a P/E ratio of -103.58 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 EPS. Analysts expect that ANI Pharmaceuticals will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.